Arranta Bio Holdings, LLC

Arranta Bio Holdings, LLC specializes in biologics development, offering innovative manufacturing solutions for advanced therapeutics, including mRNA and live biotherapeutics, aimed at pharmaceutical companies worldwide. Arranta Bio Holdings, LLC was founded in 2019 and operates from Watertown, US, focusing on the development and manufacturing of biologics. The firm has engaged in 2 deals, with the most recent on February 18, 2022. The company was acquired by Recipharm AB in February 2022 to enhance its US presence and product offerings.

The founder’s specific history was not disclosed, and no subsidiaries or parent companies are mentioned. Arranta Bio provides a comprehensive range of biologics development and manufacturing services, including the production of mRNA, lipid nanoparticles, plasmid DNA, viral vectors, and live biotherapeutics. These products support critical applications in vaccine development, gene therapy, and microbiome therapies for global pharmaceutical and biotechnology clients. The company’s expertise has expanded through strategic acquisitions, allowing it to serve diverse markets across North America, Europe, and Asia.

Revenue is generated through contracts with pharmaceutical and biotechnology companies for specific biologics development projects. The company employs a B2B model, offering project-based services that can include fixed fees and complex pricing structures. The services offered are marketed under the ReciBioPharm brand, which enhances market presence and client relationships often evolve into long-term partnerships. Looking ahead, Arranta Bio plans to leverage its recent acquisition by Recipharm AB to expand its product offerings and market presence in the US.

The acquisition, completed on February 18, 2022, aims to support growth by enhancing capabilities in biologics manufacturing. While specific new products or geographic regions for expansion were not disclosed, the focus will likely be on strengthening their operational footprint and service capabilities in the rapidly growing biologics market.